



Distribution: As Appendix 1

From: Chief Pharmaceutical Officer, Andrew Evans

Date: 25 November 2020

Reference: CEM//CPhA/2020/54a

Category: Immediate

Title: Publication Of An Interim Position Statement: Tocilizumab For Patients Admitted To ICU With Covid-19 Pneumonia (Adults)

For Action by:

Chief Pharmacists - Action as below.

Medical Directors - Action as below.

What is this about: Full details are set out below and in the attached pdf document.

Why has it been sent: For your information, action and to distribute to relevant colleagues.

Issue:

Following early positive signals of benefit from the immune modulation therapy domain of the REMAP-CAP platform trial, a UK wide position statement has been agreed to support off-label prescribing and access to tocilizumab, administered intravenously, for eligible COVID positive patients in the intensive care setting.

The interim position statement will be reviewed as further evidence becomes available, including from the REMAP-CAP trial.

Further information can be found in the attached alert.

The position statement is also attached.

To: Chief Executives of Health Boards and NHS Trusts
Medical Directors of Health Boards
Nurse Directors Health Boards
Directors of Public Health
Hospital Principals and Chief Pharmacists to action as per alert
NHS Direct
AWTTC

To: **NHS Wales Shared Services Partnership to forward to:**
HB Prescribing Advisers.